Lynparza secures European approval for type of advanced breast cancer

This article was originally published here

The latest approval for Lynparza in Europe is for its use as a monotherapy for adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth factor

The post Lynparza secures European approval for type of advanced breast cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply